Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug;13(8):1144-9.
doi: 10.3201/eid1308.070071.

Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission

Anthony D Harris  1 , Jessina C McGregor, Judith A Johnson, Sandra M Strauss, Anita C Moore, Harold C Standiford, Joan N Hebden, J Glenn Morris Jr
Affiliations

Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission

Anthony D Harris et al. Emerg Infect Dis. 2007 Aug.

Abstract

Extended-spectrum beta-lactamase (ESBL)-producing bacteria are emerging pathogens. To analyze risk factors for colonization with ESBL-producing bacteria at intensive care unit (ICU) admission, we conducted a prospective study of a 3.5-year cohort of patients admitted to medical and surgical ICUs at the University of Maryland Medical Center. Over the study period, admission cultures were obtained from 5,209 patients. Of these, 117 were colonized with ESBL-producing Escherichia coli and Klebsiella spp., and 29 (25%) had a subsequent ESBL-positive clinical culture. Multivariable analysis showed the following to be statistically associated with ESBL colonization at admission: piperacillin-tazobactam (odds ratio [OR] 2.05, 95% confidence interval [CI] 1.36-3.10), vancomycin (OR 2.11, 95% CI 1.34-3.31), age > 60 years (OR 1.79, 95% CI 1.24-2.60), and chronic disease score (OR 1.15; 95% CI 1.04-1.27). Coexisting conditions and previous antimicrobial drug exposure are thus predictive of colonization, and a large percentage of these patients have subsequent positive clinical cultures for ESBL-producing bacteria.

PubMed Disclaimer

Comment in

References

    1. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–71. 10.1086/319757 - DOI - PubMed
    1. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. 2006;119:S20–8. 10.1016/j.amjmed.2006.03.013 - DOI - PubMed
    1. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31–7. 10.1086/420816 - DOI - PubMed
    1. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother. 2006;58:205–10. 10.1093/jac/dkl199 - DOI - PubMed
    1. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–85. 10.1016/j.ajic.2004.10.001 - DOI - PubMed

Publication types

MeSH terms

Substances